Canada’s Drug Agency (CDA-AMC) recommends that Keytruda should be reimbursed by public drug plans for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumours express PD-L1 (combined positive score [CPS] ≥ 1), as determined by a validated test, as neoadjuvant treatment (before surgery) as monotherapy, continued as adjuvant treatment (after surgery) in combination with radiotherapy (RT) with or without cisplatin, and then as monotherapy, if certain conditions are met.
